LadRx Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LADX research report →
Price Chart
About the company
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer.
- CEO
- Jorge Kuri Slim
- IPO
- 1989
- Employees
- 2
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on LADX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.45K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 242316.18%
- ROIC
- 255.25%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-5,712+51.7%
- Op Income
- $-3,623,142
- Net Income
- $-1,589,685,000-397081.6%
- EPS
- $-3210.89-472289.7%
- OCF Growth
- -129337.9%
- FCF Growth
- -129337.9%
- 52W High
- $2.40
- 52W Low
- $0.01
- 50D MA
- $0.08
- 200D MA
- $0.90
- Beta
- 1.25
- RSI (14)
- 27
- Avg Volume
- 113
No earnings-call transcripts are available for LADX yet.
- Free Float
- 99.3%
- Shares Outstanding
- 495.09K
- Float Shares
- 491.71K
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 15, 24 | Caldwell Joel K | other | 5,000 |
| Jan 15, 24 | Claiborne Cary J | other | 5,000 |
| Jan 15, 24 | Simpson Jennifer K. | other | 5,000 |
| Jan 15, 24 | CALOZ JOHN Y | other | 15,000 |
| Jan 15, 24 | Snowdy Stephen | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our LADX coverage
Recent articles, reports, and earnings notes.
No research on LADX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LADX report →LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th
globenewswire.com · Mar 12
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
businesswire.com · Dec 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.